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408 Y.-Y. Su et al.eMeier method. Of the eligible patients (n Z 54), 12 (22.2%) had distant metastases (DM) at
presentation. A total of 13 (24.1%) and 15 (27.8%) primary tumors were identified by FDG
PET/CT imaging and an additional triple biopsy, respectively. The results of multivariate anal-
ysis identified smoking [pZ 0.033, 95% confidence interval (CI)Z 1.19740.342], a maximum
standardized uptake value (SUVmax) of cervical nodes  14.2 (p Z 0.035, 95% CI Z 1.134
28.029), and DM at presentation (p Z 0.031, 95% CI Z 1.257114.854) as independent pre-
dictors of 2-year OS. Specifically, patients who carried  2 risk factors showed poorer out-
comes (70.3% vs. 11.8%, p < 0.001). Fifteen study patients (27.8%) had their treatment
modified by FDG PET/CT findings. We conclude that FDG PET/CT is clinically useful in CUP pa-
tients not only for tumor staging, but also for modifying treatment regimens.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Patients with cancer of unknown primary site (CUP)
continue to pose significant clinical challenges both in Asian
and Western countries [1,2] mainly because of their het-
erogeneous clinical presentations which can lead to diag-
nostic dilemmas and lack of implementation of appropriate
therapeutic regimens [3]. The management of patients who
present with cervical lymphadenopathy and are eventually
diagnosed with CUP and cervical nodal metastases is
especially problematic for head and neck oncologists in
Taiwan [4,5]. Several CUP patients also present with distant
metastases (DM) at the time of diagnosis, making the
components of diagnostic evaluation unclear in the absence
of a primary mass [2,3]. Clinically, these patients generally
undergo a thorough diagnostic work-up [i.e., physical ex-
amination, fiberscope, computed tomography (CT) or
magnetic resonance imaging (MRI), and triple biopsy] aimed
at identifying the primary tumor site and guiding the
treatment approach. When the primary tumor continues to
remain unidentified, F-18 fluorodeoxyglucose (FDG) posi-
tron emission tomography and computed tomography (PET/
CT) should be added to the diagnostic armamentarium [6].
Previous studies have suggested the value of FDG PET/
CT not only for identifying the primary tumor site missed by
conventional diagnostic work-up, but also in the detection
of DM [7e10], which may potentially alter the therapeutic
management [6,9,11e15]. Furthermore, the early detec-
tion of an occult primary tumor may also prolong the me-
dian survive time [16].
Although the use of FDG PET/CT in CUP patients with
cervical nodal metastases is increasing because of the
above-mentioned reasons, no previous studies in the field
have been conducted in the Taiwanese population. This
lack of knowledge is surprising owing to the endemic use of
betel quid chewing in Taiwan, which is in turn related to
the recently observed increasing incidence rates of head
and neck cancer [15]. The diagnostic accuracy of FDG PET/
CT imaging in this patient group is influenced by a number
of factors, including the tumor biological behavior, size,
and anatomical location [11,17]. In addition, detailed in-
formation on tumor biology and disease status is frequently
lacking in these patients, ultimately making the formula-
tion of an accurate treatment plan difficult. All of thesefactors may explain the generally poor outcomes in CUP
patients with cervical nodal metastases. Clarifying the
priority of definitive treatment in CUP patients with cervi-
cal nodal metastases is clinically relevant in order to select
the most cost-effective approach and improve outcomes. In
this scenario, we designed the current retrospective study
with two main goals: (1) we sought to investigate the
clinical utility of FDG PET/CT in Taiwanese patients with
CUP and cervical nodal metastases; and (2) we aimed to
study the impact of F-18 FDG PET/CT on the treatment
priority in this patient group.Methods
Patient population
Between September 2006 and May 2014, we identified pa-
tients who presented with cervical lymphadenopathy
pathologically diagnosed as being metastatic lymph nodes
(either by fine needle aspiration or core needle biopsy) and
undetermined primary tumor site despite a conventional
diagnostic work-up (i.e., physical examination, fiberscope,
CT or MRI, triple biopsy). All participants were enrolled in
the Chung Gung Memorial Hospital, Taoyuan, Taiwan. Po-
tential candidates were required to have both FDG PET/CT
imaging aimed at identifying the primary tumor site and/or
DM) [6] and additional triple biopsy (regardless of the
presence of any suspicious lesion on FDG PET/CT). Patients
with a previous history of malignancy (n Z 4), incomplete
clinical data (n Z 17), or neck metastases from papillary
thyroid cancer (n Z 3) were excluded. The final study
cohort for this retrospective study consisted of 54 patients.
The general characteristics of the study participants (i.e.,
sex, age, smoking, duration of lymphadenopathy, lower
neck involvement) and FDG PET/CT imaging parameters
(i.e., SUVmax of the cervical nodes) were retrospectively
collected from medical records. The sites of triple biopsy
were selected either according to the surgeon’s clinical
judgment or based on clinical or imaging suspicion (e.g.,
suspected lesions identified on FDG PET/CT imaging). Cur-
rent smoking was defined as current use of cigarettes and/
or other tobacco products. Lower neck involvement was
considered to be present when metastatic lymph nodes
Table 1 Patient characteristics.
Variables Patients
Age (y) 55.6  10.3
Male sex 50 (92.6)
Smoking 35 (64.8)
Average duration of LAP symptom (mo) 6.0  16.8
Initial neck lymph node pathology
Metastatic SCC 42 (77.8)
Metastatic undifferentiated carcinoma 8 (14.8)
Positive for malignancy 2 (3.7)
Metastatic adenocarcinoma 2 (3.7)
Lower neck involvement 30 (55.6)
Mean SUVmax of cervical nodes on PET 10.92  5.22
Data are presented as n (%) or mean  standard deviation.
LAPZ lymphadenopathy, PETZ positron emission tomography;
SCC Z squamous cell carcinoma; SUVmax Z maximum stan-
dardized uptake value.
Risk priority in cancer of unknown primary by PET 409were identified in neck levels 4/5 or in the supraclavicular
fossa. Distant metastases were diagnosed in presence of
lesions involving distant lymph nodes, visceral organs, or
bones on FDG PET/CT images (with lesions showing a score
of  3). The Institutional Review Board of Chung Gung
Memorial Hospital approved the study.
PET/CT imaging acquisition and interpretation
All of the FDG PET/CT scans were acquired using a Dis-
covery ST 16 PET/CT scanner (GE Healthcare, Milwaukee,
WI, USA). The procedures used for image acquisition and
reconstruction have been previously described in detail
[17]. Patients fasted 46 hours before examination to
obtain a plasma glucose level < 200 mg/dL. Imaging
acquisition started 60 minutes after the intravenous injec-
tion of 370e555 MBq (10e15 mCi) of F-18 FDG. Regions of
interest were drawn all over the suspicious lesions identi-
fied on FDG PET scans ordin the event of such lesions being
absentdusing the corresponding CT images. After
measuring the highest activity within each region of inter-
est, the standardized uptake value (SUV) was calculated as
the highest activity concentration per injected dose (per
body weight in kg) after correction for the radioactive
decay. Abnormal foci of increased FDG uptake were scored
on a 5-point scale as previously described [18]. In general,
visual scores of 3e4 were considered as positive, a score of
2 indicated equivocal results, whereas scores of 0e1 were
regarded as negative. All of the FDG PET/CT images were
interpreted in consensus by two experienced nuclear
medicine physicians and one radiologist.
Treatment approach
The treatment approach was based on the results of FDG
PET/CT imaging and additional triple biopsy. Patients who
had their primary tumor identified by FDG PET/CT under-
went staging of the primary malignancy and were treated
according to established guidelines. Palliative treatment
was given to patients with DM. Definitive concurrent che-
moradiotherapy (CCRT) was started within 1 month of
diagnosis in all patients in whom both FDG PET/CT and the
additional biopsy did not identify the primary tumor and
DM. Radiotherapy (RT) was administered using 6-MV photon
beams at 2 Gray (Gy) per fraction, five fractions per week.
The initial large-field prophylactic RT dose was 46e50 Gy. A
sequential cone-down boost technique was used to escalate
the dose to the gross tumor and the involved node areas to
72e76 Gy. The gross target volume (GTV) was defined as all
of the known areas of gross regional nodal disease based on
the staging work-up. The initial clinical target volume (CTV)
for prophylaxis included all of the pharynx and neck but
spared the laryngeal box below the level of the hyoid bone.
The margins between CTV and GTV were at least 1 cm for
the initial large-field and 0.5 cm for the boost field,
respectively. All of the patients received RT with a
sequential boost technique. A 3-mm three-dimensional
margin was applied to CTV to create a planning target
volume. The minimum doses delivered to the GTV, CTV, and
planning target volume were 100%, 95%, and 90%, respec-
tively. During the RT course, concurrent chemotherapy wasadministered biweekly. The CCRT regimens were based on
intravenous cisplatin (30e40 mg/m2 weekly or 100 mg/m2
every 3 weeks) [19].Data analysis
Continuous variables are expressed as mean  standard
deviation (SD), whereas categorical data are given as
counts and percentages. All clinicopathological factors and
PET parameters were analyzed in relation to 2-year OS
using univariate and multivariate analyses which was per-
formed by logistic regression. The Youden’s index was uti-
lized as the criterion for selecting the optimum cut-off
point for the maximum SUV (SUVmax) of cervical nodes [20].
All statistical analyses were performed using the IBM SPSS
statistical package (version 21; IBM Corp., Somers, NY,
USA). A p value < 0.05 (2-tailed) was considered statisti-
cally significant.Results
Patients
The general characteristics of the 54 study patients are
summarized in Table 1. DM was identified by FDG PET/CT
imaging (i.e., lesions with a score of  3 [17]) in 12 (22.2%)
patients. The distribution of DM was as follows: distant
lymph nodes (nZ 2), bone (nZ 4), visceral organs (nZ 2),
and multiple sites (n Z 4). The follow-up was continued
until November 2015. All of the participants were followed
for at least 24 months after primary surgery or censored at
the date of the previous follow-up. The entire study cohort
was followed for a median of 24.4 months (mean,
30.9 months; range, 3.0108.8 months). The median
follow-up time of the surviving patients was 44.5 months
(mean, 52.4 months; range, 28.1108.8 months). At the
end of the study, 22 patients (40.7%) were alive and 32
patients (59.3%) were dead.
410 Y.-Y. Su et al.Identification of primary tumor sites
Of the 12 patients diagnosed with DM at presentation, eight
also had their occult primary tumor identified (i.e., lesions
with a score of  3 [17]). Specifically, six were diagnosed
with FDG PET/CT and subsequently confirmed by addition
triple biopsy, whereas two were identified with additional
triple biopsy only. In patients without DM (n Z 42), seven
and 13 primary tumors were successfully diagnosed by FDG
PET/CT and additional triple biopsy, respectively. In total,
FDG PET/CT and additional triple biopsy were able to
identify 13 (24.1%) and 15 (27.8%) primary tumors,Figure 1. Representative images of a 57-year-old male patient di
a strong uptake (SUVmaxZ 9.6) in the middle third esophagus; this l
only revealed the presence of a necrotic lymph node in the level
responding FDG PET/CT image; Panel C). CT Z computed tomogra
tomography.respectively. A representative case is illustrated in
Figure 1.
Among the eight primary tumors identified in patients
with DM, the six diagnosed by FDG PET/CT imaging had the
following distribution: oropharyngeal cancer (n Z 1),
esophageal cancer (nZ 3), lung cancer (nZ 1), and gastric
cancer (n Z 1). The remaining two malignancies identified
with repeated triple biopsy only were oropharyngeal neo-
plasms (Table 2).
In patients without DM (n Z 42), the seven tumors
diagnosed by FDG PET/CT imaging had the following dis-
tribution: nasopharyngeal cancer (n Z 3), oropharyngealagnosed with esophageal cancer. FDG PET/CT imaging revealed
esion was assigned a score of 4 (Panels A and B). By contrast, CT
IV area of the neck (which showed a SUVmax of 4.7 on the cor-
phy; FDGZ F-18 fluorodeoxyglucose; PET Z positron emission
Table 2 Distribution of primary tumor sites identified in
the current study.
Primary tumor sites PET findings
M0 (n) M1 (n)
TP FN TP FN
Head & neck
Nasopharynx 3 1
Oral cavity 2
Oropharynx 3 7 1 2
Hypopharynx 3
Esophagus 1 3
Lung 1
Gastric 1
Overall 7 13 6 2
FN Z false negative, FP Z false positive, TP Z true positive.
Risk priority in cancer of unknown primary by PET 411cancer (n Z 3), and esophageal cancer (n Z 1). Thirteen
additional malignancies were identified with repeated tri-
ple biopsy, as follows: nasopharyngeal cancer (nZ 1), oral
cavity cancer (n Z 2), oropharyngeal cancer (n Z 7), and
hypopharyngeal cancer (n Z 3). Occult primary tumors
located in the oral cavity, oropharynx, or hypopharynx had
poor detection rates on FDG PET/CT (Table 2).Risk stratification
Table 3 depicts the results of univariate and multivariate
analyses in the 54 patients with CUP and cervical nodal
metastases. Univariate analysis identified smoking, lower
neck lymph nodes (level 4, 5, or supraclavicular fossa)
involvement on FDG PET/CT imaging, SUVmax of cervical
nodes  14.2, and DM as significantly associated with the 2-
year cumulative OS. Other risk factorsdincluding duration
of lymphadenopathy < 5 months, bilateral cervical lymph
nodes involvement on PET/CT imaging, and no identifica-
tion of the occult primary tumordwere not significantly
associated with 2-year OS on univariate analysis. After
allowance for potential confounders in multivariate anal-
ysis, smoking, SUVmax of the cervical nodes, and DM were
identified as significant independent predictors of 2-year OS
rates. Patients were then divided into different risk groups
based on a score obtained by assigning one point for each
independent risk factor. There were 37 patients with aTable 3 Univariate and multivariate analyses of risk factors ass
Parameter (n) Univariate
95% CI
Smoking 1.234e14.294
Lower neck nodes involvement on PET 1.815e19.837
Bilateral neck nodes involvement on PET 1.001e14.050
SUVmax of cervical lymph nodes  14.2 1.120e12.001
Initial distant metastases 1.575e41.926
Unidentified occult primary tumor sites 0.531e4.566
CI Z confidence interval; HR Z hazard ratio; PET Z positron emissioscore of 01, whereas 17 patients had a score of 23. The
2-year OS rates in the two groups were 70.3% and 11.8%,
respectively (p < 0.001; Figure 2).Discussion
Head and neck cancer continues to pose a significant health
burden to Asian countries, and cervical nodal metastases
are common in this clinical entity. Notably, mounting evi-
dence indicates that FDG PET/CT may be clinically useful
for detecting occult primary neoplasms and/or DM, ulti-
mately influencing the clinical management of this patient
group [9,10,16,21e23]. Current curative-intent treatment
plans for patients with malignancies are largely dependent
on disease status and the nature of the primary tumor.
Unfortunately, tailored treatment plans for patient with
CUP remain difficult to develop. Starting from these pre-
mises, this study was specifically designed to investigate
the potential utility of FDG PET/CT in CUP patients pre-
senting with cervical nodal metastases.
The mean detection rate of occult neoplasms and/or DM
in our study was 24.1%, a finding in line with the previous
literature (showing a mean detection rate ofw25%) [11]. As
expected, 78.6% (22/28) of the primary tumors identified in
our CUP patients were head and neck malignancies. How-
ever, only seven of these 22 neoplasms (31.8%) were diag-
nosed with FDG PET/CT. This phenomenon may be
explained by the known limitations of FDG PET/CT imaging
including the small size of the primary tumor
(lesions < 7 mm in their short axis are frequently unde-
tectable) and/or the presence of a high FDG background
activity in the tumor area (due to physiological uptake in
the salivary glands, inflammatory reactions, and/or the
presence of lymphoid tissue). The latter issue can ulti-
mately degrade the quality of PET scans by reducing the
lesion-to-background ratio [15,16]. In this scenario, further
studies are necessary to identify the optimal cut-off points
for PET-derived parameters in the identification of occult
primary tumors. In our study, we found that FDG PET/CT
imaging was more sensitive in the detection of: (1) naso-
pharyngeal cancer; and (2) malignancies located outside of
the head and neck area (a finding in line with previous
observations [22]). By contrast, 68.2% (15/22) of all head
and neck tumors were identified by additional triple biopsy.
The sites of additional triple biopsy were selected accord-
ing to the results of FDG PET/CT, clinical suspicion, and/or
based on the surgeon’s judgment. The high clinicalociated with 2-year overall survival.
analyses Multivariate analyses
HR p 95% CI HR p
4.200 0.022 1.197e40.342 6.948 0.031
6.000 0.003 0.561e11.277 2.516 0.228
3.750 0.050 d d d
5.143 0.032 1.134e28.029 5.638 0.035
8.125 0.012 1.257e114.854 12.017 0.031
0.643 0.420 d d d
n tomography; SUVmax, maximum standardized uptake value.
Figure 2. Flowchart of risk stratification for the study participants. caZ carcinoma; LNZ lymph nodes; OSZ overall survival;
SUVmax: maximum standardized uptake value.
412 Y.-Y. Su et al.experience of the surgeons involved in the study may
explain the higher positive rates associated with the use of
additional triple biopsy. Based on these findings, we believe
that repeated triple biopsy should be recommended to all
patients with CUP and negative FDG PET/CT findings.
In addition to disease staging, FDG PET/CT can be clin-
ically useful for risk stratification of this patient group
[24,25]. Our results are in line with those of a previous
report showing that smoking, high SUV values of the cer-
vical nodes, and DM predict poor outcomes [1,26e28].
However, it should be noted that an unidentified occult
primary tumor and bilateral cervical nodal metastases were
not independently associated with 2-year OS in our report,
a finding at variance with the published literature [29,30].
Smoking is a well-known risk factor for a number of
different malignancies, including CUP [25]. We also
demonstrated that it can serve as an independent predictor
of OS in CUP patients. Unfortunately, we did not specifically
investigate the amount of smoking (a variable that could
have had an impact on our findings). The adverse prognostic
significance of cervical SUVmax and DM at presentation
could reflect a high biological tumor aggressiveness in pa-
tients with CUP and cervical nodal metastases, ultimately
serving as an unfavorable prognostic biomarker.
Curative-intent treatment for patients with CUP who
present with cervical lymph nodes metastases consists of
neck node dissection, postoperative radiotherapy, and/or
CCRT [11,17]. Several different chemotherapy and RT regi-
mens have been investigated so far, generally resulting in
acceptable outcomes (despite some expected complications)
[28,29]. In the absence of DM, it is our policy to treat all pa-
tients with CUP and cervical lymph nodes metastases with
curative-intent CCRT. In this scenario, an improved prog-
nostic stratification is paramount to avoid overly aggressive or
futile treatments. We therefore believe that our current
prognostic scoring system may be useful in this setting.
Although the generalizability of our findings may be
limited by the small sample size and the retrospective
single-center nature of our research, all of the studyparticipants were followed by an expert multidisciplinary
head and neck care team. Altogether, our data may
represent a valuable addition to the literature on the po-
tential clinical utility of FDG PET/CT imaging in Asian pa-
tients with CUP presenting with cervical node metastases.
In conclusion, our results indicate that approximately
one-third of patients with CUP and cervical node metasta-
ses had their treatment modified by FDG PET/CT findings
(through the identification of the occult primary tumor
and/or DM). The priority of definitive treatment for pa-
tients with CUP and cervical node metastases can be
stratified according to FDG PET/CT results.References
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